The role of Notch ligand, Delta-like ligand 4 (DLL4), in cancer angiogenesis—implications for therapy
ConclusionDLL4 seems to be a promising target in anti-cancer therapy. Nevertheless, the careful evaluation of adverse effects on normal physiological processes in relation to therapeutic doses of anti-DLL4 drugs will be significant for advancement of DLL4 blocking agents in clinical oncology.
Source: European Surgery - Category: Surgery Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Cancer Vaccines | Science | Surgery | Vaccines